evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

537 questions · 560 findings · 45 reviews · Common Mental Disorders

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 105 · 18.8%GRADE not reported 8 · 1.4%Very low 170 · 30.4%Low 153 · 27.3%Moderate 94 · 16.8%High 30 · 5.4%

Valproate vs placebo

Change in symptom severity at 3 weeks (secondary efficacy outcome) · Adults (aged 18 and over) with acute mania
1 finding from 1 review

Valproate vs placebo

Dropout · Adults (aged 18 and over) with acute mania

Valproate showed no clear difference in dropout rate ‐ All‐cause 3‐8 weeks (secondary acceptability outcome) compared with placebo (moderate certainty).

1 finding from 1 review

Valproate vs placebo

Response rate at 8 weeks (primary efficacy outcome) · Children and adolescents with acute mania

It is very uncertain whether valproate changes response rate at 4 weeks (primary efficacy outcome) compared with placebo (very low certainty).

1 finding from 1 review

Valproate vs placebo

Primary outcome 3: Adverse events · Children and adolescents with acute mania

It is very uncertain whether valproate changes number with any adverse event at 4 weeks (primary tolerability… compared with placebo (very low certainty).

1 finding from 1 review

Valproate vs placebo

Adverse effects: 1. Sedation · Children and adolescents with acute mania

It is very uncertain whether valproate changes individual adverse events ‐ Sedation At 4 weeks (secondary… compared with placebo (very low certainty).

1 finding from 1 review

Valproate vs placebo

Change in symptom severity at 3 weeks (secondary efficacy outcome) · Children and adolescents with acute mania
1 finding from 1 review

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Leaving the study early · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in dropouts compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).

1 finding from 1 review

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Response (≥ 50% improvement in BDI‐II score) · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in response (≥ 50% improvement in BDI‐II score) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).

1 finding from 1 review

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Remission · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in remission (BDI‐II total score ≤ 9) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).

1 finding from 1 review

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

Leaving the study early · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI) with busiprone (20… showed no clear difference in dropouts compared with augmentation of current antidepressant (SSRI) with placebo (low certainty).

1 finding from 1 review

Augmentation of current antidepressant (various) with cariprazine (1 mg/d to 4.5 mg/d) vs augmentation of current antidepressant (various) with placebo

Dropouts ‐ Any dose · treatment‐resistant depression in adults

Augmentation of current antidepressant (various) with cariprazine (1… probably leads to higher dropouts ‐ any dose compared with augmentation of current antidepressant (various) with placebo (moderate certainty).

1 finding from 1 review

Augmentation of current antidepressant (various) with cariprazine (1 mg/d to 4.5 mg/d) vs augmentation of current antidepressant (various) with placebo

> 50% reduction in depressive symptoms · treatment‐resistant depression in adults

Augmentation of current antidepressant (various) with cariprazine (1… probably leads to higher response (≥ 50% improvement in MADRS score) ‐ any dose compared with augmentation of current antidepressant (various) with placebo (moderate certainty).

1 finding from 1 review